Rezolute says FDA recommends pre-BLA meeting for ersodetug in congenital hyperinsulinism

• Rezolute received an FDA recommendation to hold a Type B pre-BLA meeting ahead of a potential filing for ersodetug in congenital hyperinsulinism.
• The Phase 3 sunRIZE study showed glycemic improvement, but missed its primary endpoint, limiting the strength of the main efficacy claim.
• FDA reviewed extensive continuous glucose monitoring analyses, then urged a pre-BLA discussion without taking a position on approvability.
• Topline Phase 3 upLIFT results in tumor-related hyperinsulinism are expected this quarter, shaping the broader BLA submission strategy.
• An open-label extension remains ongoing, supporting longer-term treatment experience and potential durability of benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839272) on October 05, 2026, and is solely responsible for the information contained therein.